Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

New Phase III Trial

August 19th 2013

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Dr. Lenz Describes Excitement Over Advances in GI Cancer

August 16th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

RAS Mutation Status Key to Panitumumab Use in mCRC

July 30th 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

Dr. Venook on Using Frailty Index & Geriatric Assessments

July 17th 2013

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the importance of utilizing frailty index and geriatric assessments for patients with cancer.

Dr. Kaufman on the Importance of the Immunoscore

July 16th 2013

Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer.

Dr. Link on Algenpantucel-L for Pancreatic Cancer

July 15th 2013

Charles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.

Dr. Tabernero on Molecular Characterization in GI Cancer

July 12th 2013

Josep Tabernero, MD, PhD, from the Vall d'Hebron University Hospital, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Dr. Marc Peeters on the Aflibercept Toxicity Profile

July 9th 2013

Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.

IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

July 6th 2013

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

July 6th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening

July 6th 2013

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept

July 6th 2013

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Dr. Ruff on Selecting Anti- Angiogenic Agents in mCRC

July 5th 2013

Paul Ruff, MD, from the University of Witwatersrand, Johannesburg, South Africa, elaborates on factors that can be utilized to select an appropriate antiangiogenic therapy as a second-line treatment in metastatic colorectal cancer.

Nab-paclitaxel Plus Gemcitabine a Strong Predictor of Survival in Metastatic Pancreatic Cancer

July 4th 2013

Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.

Gemcitabine Response Depends on Gene Expression in Patients With Pancreatic Cancer

July 4th 2013

Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.

Dr. Venook on Geographic Variations in Treatments

July 4th 2013

Alan P. Venook, MD, from the University of California, San Francisco, describes factors that contribute to the geographic variations seen in therapies utilized to treat cancer in the United States and Europe.

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. Heinemann Reviews the FIRE-3 Trial Results

June 2nd 2013

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

June 2nd 2013

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.